Kathryn Horwitz
Concepts (514)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Progesterone | 112 | 2020 | 337 | 9.970 |
Why?
| | Breast Neoplasms | 119 | 2021 | 2257 | 5.890 |
Why?
| | Progesterone | 47 | 2021 | 263 | 4.870 |
Why?
| | Receptors, Estrogen | 57 | 2014 | 412 | 3.780 |
Why?
| | Progestins | 23 | 2021 | 81 | 2.630 |
Why?
| | Estrogens | 17 | 2014 | 368 | 1.890 |
Why?
| | Gene Expression Regulation, Neoplastic | 21 | 2015 | 1435 | 1.740 |
Why?
| | Tamoxifen | 26 | 2012 | 203 | 1.640 |
Why?
| | Transcription, Genetic | 29 | 2012 | 1487 | 1.560 |
Why?
| | Estradiol | 28 | 2014 | 528 | 1.530 |
Why?
| | SUMO-1 Protein | 4 | 2012 | 21 | 0.920 |
Why?
| | Tumor Cells, Cultured | 32 | 2009 | 962 | 0.750 |
Why?
| | Keratin-5 | 4 | 2014 | 49 | 0.710 |
Why?
| | Gene Expression Profiling | 13 | 2014 | 1771 | 0.700 |
Why?
| | Neoplasms, Hormone-Dependent | 8 | 2010 | 38 | 0.670 |
Why?
| | Promegestone | 24 | 2005 | 33 | 0.640 |
Why?
| | Transcription Factors | 12 | 2009 | 1712 | 0.610 |
Why?
| | Gene Expression Regulation | 10 | 2011 | 2608 | 0.600 |
Why?
| | Stromal Cells | 5 | 2014 | 117 | 0.580 |
Why?
| | Biomarkers, Tumor | 8 | 2020 | 1258 | 0.580 |
Why?
| | Cell Proliferation | 9 | 2014 | 2506 | 0.570 |
Why?
| | Protein Processing, Post-Translational | 4 | 2013 | 464 | 0.540 |
Why?
| | HeLa Cells | 15 | 2012 | 640 | 0.540 |
Why?
| | Estrogen Replacement Therapy | 2 | 2008 | 142 | 0.530 |
Why?
| | Promoter Regions, Genetic | 12 | 2012 | 1243 | 0.530 |
Why?
| | Female | 106 | 2021 | 75943 | 0.510 |
Why?
| | Humans | 157 | 2021 | 141754 | 0.500 |
Why?
| | Cell Line, Tumor | 19 | 2014 | 3495 | 0.490 |
Why?
| | Medroxyprogesterone Acetate | 3 | 2005 | 39 | 0.490 |
Why?
| | Cell Nucleus | 27 | 2008 | 609 | 0.460 |
Why?
| | Neovascularization, Pathologic | 2 | 2014 | 296 | 0.460 |
Why?
| | Mifepristone | 11 | 2000 | 63 | 0.460 |
Why?
| | Antineoplastic Agents, Hormonal | 6 | 2010 | 170 | 0.450 |
Why?
| | Down-Regulation | 9 | 2009 | 641 | 0.450 |
Why?
| | Neoplastic Stem Cells | 3 | 2008 | 408 | 0.450 |
Why?
| | Lymphatic Metastasis | 4 | 2010 | 326 | 0.440 |
Why?
| | Phosphorylation | 19 | 2013 | 1774 | 0.440 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2014 | 93 | 0.440 |
Why?
| | Molecular Sequence Data | 21 | 2009 | 2929 | 0.440 |
Why?
| | Histone Acetyltransferases | 4 | 2012 | 63 | 0.430 |
Why?
| | Animals | 54 | 2014 | 37749 | 0.430 |
Why?
| | Epigenomics | 1 | 2015 | 114 | 0.430 |
Why?
| | Mice | 27 | 2014 | 18109 | 0.420 |
Why?
| | Epidermal Growth Factor | 8 | 2005 | 176 | 0.420 |
Why?
| | Transcriptional Activation | 9 | 2009 | 378 | 0.420 |
Why?
| | Epithelium | 3 | 2013 | 316 | 0.400 |
Why?
| | Mice, Nude | 9 | 2012 | 691 | 0.390 |
Why?
| | Cell Division | 12 | 2003 | 798 | 0.370 |
Why?
| | Cell Line | 35 | 2009 | 2887 | 0.370 |
Why?
| | Protein Isoforms | 6 | 2011 | 398 | 0.370 |
Why?
| | MCF-7 Cells | 4 | 2020 | 126 | 0.360 |
Why?
| | Binding Sites | 15 | 2006 | 1316 | 0.360 |
Why?
| | DNA-Binding Proteins | 10 | 2000 | 1485 | 0.350 |
Why?
| | Enzyme Inhibitors | 3 | 2008 | 855 | 0.350 |
Why?
| | Repressor Proteins | 5 | 2002 | 430 | 0.350 |
Why?
| | Signal Transduction | 18 | 2012 | 5169 | 0.350 |
Why?
| | Models, Biological | 5 | 2014 | 1828 | 0.340 |
Why?
| | Cyclins | 4 | 1999 | 92 | 0.340 |
Why?
| | Neoplasm Proteins | 4 | 2005 | 434 | 0.340 |
Why?
| | DNA | 11 | 2000 | 1444 | 0.340 |
Why?
| | Receptors, Notch | 1 | 2011 | 87 | 0.340 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2010 | 9 | 0.330 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 663 | 0.320 |
Why?
| | DNA Methylation | 1 | 2015 | 648 | 0.310 |
Why?
| | Peritoneal Neoplasms | 1 | 2010 | 102 | 0.310 |
Why?
| | Transplantation, Heterologous | 6 | 2009 | 193 | 0.310 |
Why?
| | Adenocarcinoma | 2 | 2014 | 896 | 0.310 |
Why?
| | Nuclear Proteins | 7 | 2000 | 719 | 0.310 |
Why?
| | Alu Elements | 1 | 2009 | 28 | 0.300 |
Why?
| | Milk Proteins | 2 | 1999 | 35 | 0.300 |
Why?
| | Neoplasm Transplantation | 4 | 2014 | 250 | 0.290 |
Why?
| | Neoplasm Metastasis | 5 | 2020 | 676 | 0.290 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2010 | 833 | 0.280 |
Why?
| | Amino Acid Sequence | 12 | 2009 | 2158 | 0.280 |
Why?
| | Protein Multimerization | 1 | 2009 | 194 | 0.280 |
Why?
| | Nuclear Receptor Coactivator 1 | 4 | 2012 | 11 | 0.280 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 58 | 0.270 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2013 | 1078 | 0.270 |
Why?
| | Cyclic AMP | 5 | 2006 | 219 | 0.260 |
Why?
| | Cysteine Endopeptidases | 3 | 2012 | 74 | 0.260 |
Why?
| | Ligands | 10 | 2009 | 667 | 0.260 |
Why?
| | Saccharomyces cerevisiae Proteins | 2 | 2001 | 403 | 0.260 |
Why?
| | Cell Fusion | 1 | 2006 | 50 | 0.250 |
Why?
| | Breast | 5 | 2001 | 158 | 0.240 |
Why?
| | Selective Estrogen Receptor Modulators | 2 | 2010 | 32 | 0.240 |
Why?
| | Models, Theoretical | 2 | 2008 | 584 | 0.240 |
Why?
| | Trans-Activators | 5 | 1999 | 394 | 0.230 |
Why?
| | Base Sequence | 11 | 2009 | 2180 | 0.230 |
Why?
| | DNA, Neoplasm | 6 | 1992 | 158 | 0.220 |
Why?
| | Protein Binding | 10 | 2009 | 2242 | 0.220 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 581 | 0.210 |
Why?
| | Epithelial Cells | 2 | 2010 | 1114 | 0.210 |
Why?
| | RNA, Messenger | 11 | 2010 | 2828 | 0.210 |
Why?
| | Gonanes | 5 | 1997 | 27 | 0.210 |
Why?
| | Drug Resistance | 8 | 2000 | 150 | 0.210 |
Why?
| | Lymph Nodes | 1 | 2006 | 502 | 0.200 |
Why?
| | Cell Growth Processes | 3 | 2010 | 53 | 0.200 |
Why?
| | Estrogen Receptor Modulators | 3 | 2008 | 17 | 0.200 |
Why?
| | Receptors, Steroid | 4 | 1999 | 46 | 0.200 |
Why?
| | Sumoylation | 2 | 2013 | 16 | 0.200 |
Why?
| | Molecular Weight | 11 | 2000 | 329 | 0.200 |
Why?
| | Mutation | 7 | 2012 | 4015 | 0.200 |
Why?
| | Peptide Fragments | 5 | 2003 | 701 | 0.190 |
Why?
| | Receptors, Cell Surface | 7 | 1994 | 398 | 0.190 |
Why?
| | ErbB Receptors | 4 | 2020 | 610 | 0.190 |
Why?
| | Disease Models, Animal | 4 | 2014 | 4421 | 0.190 |
Why?
| | Phosphoserine | 2 | 2000 | 32 | 0.180 |
Why?
| | Norpregnadienes | 3 | 1988 | 6 | 0.180 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 174 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2012 | 907 | 0.170 |
Why?
| | Leucine Zippers | 3 | 1997 | 16 | 0.170 |
Why?
| | Immunohistochemistry | 6 | 2008 | 1739 | 0.170 |
Why?
| | Transfection | 8 | 2006 | 943 | 0.170 |
Why?
| | Multienzyme Complexes | 2 | 2003 | 66 | 0.170 |
Why?
| | Antibodies, Monoclonal | 9 | 2006 | 1474 | 0.170 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2000 | 317 | 0.170 |
Why?
| | Antigens, Nuclear | 1 | 2000 | 16 | 0.160 |
Why?
| | Recombinant Fusion Proteins | 6 | 2000 | 674 | 0.160 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 987 | 0.160 |
Why?
| | Homeodomain Proteins | 3 | 2009 | 515 | 0.160 |
Why?
| | Estrogen Antagonists | 11 | 2000 | 45 | 0.160 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2000 | 100 | 0.160 |
Why?
| | Response Elements | 3 | 2009 | 90 | 0.150 |
Why?
| | Prolactin | 2 | 1998 | 96 | 0.150 |
Why?
| | Receptor Cross-Talk | 1 | 1998 | 21 | 0.150 |
Why?
| | Kinetics | 15 | 2001 | 1655 | 0.150 |
Why?
| | Amino Acid Motifs | 3 | 2006 | 225 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2021 | 353 | 0.150 |
Why?
| | Hormone Antagonists | 2 | 1997 | 34 | 0.150 |
Why?
| | MAP Kinase Signaling System | 2 | 2001 | 326 | 0.150 |
Why?
| | DNA Helicases | 1 | 2000 | 142 | 0.140 |
Why?
| | Tumor Suppressor Proteins | 2 | 1998 | 326 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2020 | 215 | 0.140 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 859 | 0.140 |
Why?
| | Risk | 1 | 2021 | 907 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-fos | 2 | 1998 | 191 | 0.140 |
Why?
| | Progesterone Congeners | 5 | 2008 | 15 | 0.140 |
Why?
| | Affinity Labels | 9 | 1990 | 24 | 0.140 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 4 | 1999 | 122 | 0.140 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2010 | 761 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 2 | 2012 | 132 | 0.140 |
Why?
| | Oxygenases | 1 | 1997 | 13 | 0.140 |
Why?
| | CDC2-CDC28 Kinases | 1 | 1997 | 18 | 0.140 |
Why?
| | Mutagenesis, Site-Directed | 5 | 2001 | 377 | 0.140 |
Why?
| | Nafoxidine | 8 | 1982 | 9 | 0.130 |
Why?
| | Endometrium | 2 | 2008 | 61 | 0.130 |
Why?
| | Phosphoproteins | 3 | 2008 | 338 | 0.130 |
Why?
| | Immunoblotting | 4 | 2004 | 310 | 0.130 |
Why?
| | Endopeptidases | 2 | 2012 | 86 | 0.130 |
Why?
| | Hyaluronan Receptors | 2 | 2008 | 103 | 0.130 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 2 | 1994 | 21 | 0.130 |
Why?
| | Endometrial Neoplasms | 4 | 2008 | 197 | 0.130 |
Why?
| | Ribosomal Proteins | 1 | 1997 | 92 | 0.130 |
Why?
| | Carcinoma, Endometrioid | 2 | 2008 | 50 | 0.130 |
Why?
| | Cytoplasm | 12 | 2006 | 273 | 0.130 |
Why?
| | Carcinogens | 1 | 1997 | 128 | 0.130 |
Why?
| | Up-Regulation | 3 | 2009 | 860 | 0.130 |
Why?
| | Muscle, Smooth, Vascular | 4 | 2000 | 450 | 0.120 |
Why?
| | Cluster Analysis | 4 | 2008 | 521 | 0.120 |
Why?
| | Microtubule-Associated Proteins | 1 | 1997 | 198 | 0.120 |
Why?
| | Mammary Neoplasms, Experimental | 8 | 2009 | 68 | 0.120 |
Why?
| | Blotting, Western | 6 | 2010 | 1234 | 0.120 |
Why?
| | Apoptosis | 5 | 2011 | 2576 | 0.120 |
Why?
| | Receptors, Glucocorticoid | 8 | 2000 | 137 | 0.120 |
Why?
| | Consensus Sequence | 2 | 2009 | 74 | 0.120 |
Why?
| | Phenotype | 5 | 2011 | 3177 | 0.110 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1996 | 209 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 1994 | 57 | 0.110 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 703 | 0.110 |
Why?
| | Methylation | 1 | 2015 | 230 | 0.110 |
Why?
| | Heterografts | 1 | 2014 | 134 | 0.110 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 108 | 0.100 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2014 | 193 | 0.100 |
Why?
| | Small Molecule Libraries | 1 | 2014 | 98 | 0.100 |
Why?
| | Fibroblasts | 2 | 2020 | 1021 | 0.100 |
Why?
| | Estrenes | 4 | 1989 | 16 | 0.100 |
Why?
| | Ubiquitination | 1 | 2013 | 107 | 0.100 |
Why?
| | Immunoenzyme Techniques | 2 | 2010 | 209 | 0.100 |
Why?
| | Cell Cycle Proteins | 1 | 1997 | 632 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2006 | 467 | 0.100 |
Why?
| | Immunophenotyping | 1 | 2014 | 329 | 0.100 |
Why?
| | Acetylation | 1 | 2013 | 245 | 0.100 |
Why?
| | Drug Synergism | 4 | 1998 | 375 | 0.100 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 26 | 0.100 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2013 | 57 | 0.100 |
Why?
| | Chickens | 6 | 1994 | 189 | 0.090 |
Why?
| | DNA, Complementary | 4 | 2001 | 274 | 0.090 |
Why?
| | Carcinoma, Lobular | 1 | 2012 | 53 | 0.090 |
Why?
| | Bone Neoplasms | 1 | 2014 | 253 | 0.090 |
Why?
| | Disease Progression | 3 | 2014 | 2800 | 0.090 |
Why?
| | Claudins | 1 | 2011 | 24 | 0.090 |
Why?
| | Cytosol | 9 | 1989 | 230 | 0.090 |
Why?
| | Cells, Cultured | 10 | 2006 | 4212 | 0.090 |
Why?
| | Bridged-Ring Compounds | 1 | 2011 | 27 | 0.090 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 24 | 0.090 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2011 | 79 | 0.090 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 3 | 2000 | 15 | 0.090 |
Why?
| | Polyploidy | 1 | 1990 | 13 | 0.080 |
Why?
| | Estrogen Receptor alpha | 2 | 2010 | 144 | 0.080 |
Why?
| | Neoplasms, Experimental | 4 | 2008 | 174 | 0.080 |
Why?
| | Taxoids | 1 | 2011 | 102 | 0.080 |
Why?
| | Pyrrolidines | 3 | 1981 | 111 | 0.080 |
Why?
| | Acetylcysteine | 2 | 2003 | 144 | 0.080 |
Why?
| | Receptor, Insulin | 3 | 1985 | 100 | 0.080 |
Why?
| | Genome, Human | 1 | 2013 | 421 | 0.080 |
Why?
| | COS Cells | 2 | 2003 | 183 | 0.080 |
Why?
| | Hormones | 2 | 1993 | 140 | 0.080 |
Why?
| | Cloning, Molecular | 4 | 2006 | 533 | 0.080 |
Why?
| | Organ Specificity | 1 | 2010 | 312 | 0.080 |
Why?
| | Chemokine CXCL12 | 1 | 2010 | 84 | 0.080 |
Why?
| | Histones | 1 | 2015 | 639 | 0.080 |
Why?
| | Epitopes | 1 | 1991 | 477 | 0.080 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 2 | 2000 | 14 | 0.080 |
Why?
| | Antineoplastic Agents | 2 | 2008 | 2169 | 0.080 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2009 | 156 | 0.080 |
Why?
| | Transformation, Genetic | 1 | 1988 | 16 | 0.070 |
Why?
| | Receptors, Androgen | 5 | 2005 | 153 | 0.070 |
Why?
| | Time Factors | 4 | 2008 | 6966 | 0.070 |
Why?
| | STAT5 Transcription Factor | 2 | 1999 | 57 | 0.070 |
Why?
| | Drug Administration Routes | 1 | 2008 | 41 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2000 | 151 | 0.070 |
Why?
| | Embryonal Carcinoma Stem Cells | 1 | 2008 | 2 | 0.070 |
Why?
| | Neoadjuvant Therapy | 2 | 2010 | 424 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2000 | 184 | 0.070 |
Why?
| | Protein Precursors | 1 | 1989 | 134 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 692 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2014 | 741 | 0.070 |
Why?
| | Substrate Specificity | 1 | 2009 | 385 | 0.070 |
Why?
| | Transcriptome | 1 | 2014 | 1014 | 0.070 |
Why?
| | Microdissection | 1 | 2007 | 15 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 78 | 0.070 |
Why?
| | Mammary Tumor Virus, Mouse | 2 | 2000 | 45 | 0.070 |
Why?
| | Dactinomycin | 4 | 1981 | 30 | 0.070 |
Why?
| | Binding, Competitive | 6 | 1994 | 196 | 0.070 |
Why?
| | Pregnanes | 1 | 1986 | 3 | 0.060 |
Why?
| | Lasers | 1 | 2007 | 130 | 0.060 |
Why?
| | Structure-Activity Relationship | 2 | 2002 | 579 | 0.060 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 64 | 0.060 |
Why?
| | Recombinant Proteins | 3 | 2003 | 1363 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 771 | 0.060 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 510 | 0.060 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 498 | 0.060 |
Why?
| | Pregnanolone | 1 | 1986 | 42 | 0.060 |
Why?
| | Menopause | 3 | 2008 | 320 | 0.060 |
Why?
| | Mutant Proteins | 1 | 2006 | 102 | 0.060 |
Why?
| | Protein Biosynthesis | 3 | 2000 | 444 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2005 | 2064 | 0.060 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2006 | 47 | 0.060 |
Why?
| | Cell Cycle | 2 | 1999 | 600 | 0.060 |
Why?
| | Pleural Effusion | 1 | 2006 | 61 | 0.060 |
Why?
| | Zinc Fingers | 2 | 1998 | 50 | 0.060 |
Why?
| | Chromatography, Affinity | 4 | 1990 | 86 | 0.060 |
Why?
| | Methionine | 2 | 2000 | 159 | 0.060 |
Why?
| | Regulatory Sequences, Nucleic Acid | 3 | 1997 | 92 | 0.060 |
Why?
| | Chromosome Mapping | 4 | 1999 | 504 | 0.060 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 368 | 0.060 |
Why?
| | Uterine Neoplasms | 1 | 2006 | 92 | 0.060 |
Why?
| | Hydroxyprogesterones | 1 | 1985 | 1 | 0.060 |
Why?
| | Gene Regulatory Networks | 1 | 2007 | 313 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2014 | 1305 | 0.060 |
Why?
| | Keratins | 1 | 2005 | 173 | 0.060 |
Why?
| | Thromboplastin | 1 | 2004 | 73 | 0.060 |
Why?
| | Cycloheximide | 4 | 1989 | 53 | 0.050 |
Why?
| | Chloramphenicol O-Acetyltransferase | 2 | 1994 | 36 | 0.050 |
Why?
| | Dimerization | 2 | 2002 | 196 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2006 | 334 | 0.050 |
Why?
| | Dexamethasone | 5 | 2000 | 380 | 0.050 |
Why?
| | Protein Conformation | 2 | 2001 | 941 | 0.050 |
Why?
| | Patient Care Planning | 1 | 2005 | 155 | 0.050 |
Why?
| | Microscopy, Confocal | 1 | 2004 | 324 | 0.050 |
Why?
| | Cell Movement | 2 | 2006 | 990 | 0.050 |
Why?
| | Paclitaxel | 1 | 2004 | 237 | 0.050 |
Why?
| | Plasmids | 2 | 2002 | 365 | 0.050 |
Why?
| | Genes, Reporter | 2 | 1994 | 274 | 0.050 |
Why?
| | Cell Adhesion | 1 | 2004 | 469 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 4190 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2003 | 161 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2005 | 1321 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2003 | 363 | 0.050 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 391 | 0.050 |
Why?
| | Mutagenesis | 1 | 2003 | 182 | 0.050 |
Why?
| | Oligodeoxyribonucleotides | 2 | 1993 | 143 | 0.050 |
Why?
| | Flow Cytometry | 3 | 1992 | 1197 | 0.050 |
Why?
| | Uterus | 1 | 2003 | 222 | 0.050 |
Why?
| | Biomedical Research | 1 | 2008 | 708 | 0.050 |
Why?
| | Testosterone | 1 | 2005 | 405 | 0.050 |
Why?
| | MAP Kinase Kinase Kinase 1 | 1 | 2001 | 19 | 0.040 |
Why?
| | Iron Chelating Agents | 1 | 2001 | 19 | 0.040 |
Why?
| | Oligonucleotide Probes | 2 | 1992 | 50 | 0.040 |
Why?
| | Growth Substances | 2 | 1999 | 148 | 0.040 |
Why?
| | Androgens | 7 | 1986 | 187 | 0.040 |
Why?
| | Oviducts | 3 | 1986 | 15 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2567 | 0.040 |
Why?
| | Cell Differentiation | 2 | 2006 | 2006 | 0.040 |
Why?
| | Ultracentrifugation | 1 | 2001 | 52 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 554 | 0.040 |
Why?
| | Gene Library | 2 | 1992 | 120 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2001 | 183 | 0.040 |
Why?
| | Pregnancy | 2 | 2013 | 7092 | 0.040 |
Why?
| | Genetic Variation | 2 | 1999 | 1000 | 0.040 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2000 | 37 | 0.040 |
Why?
| | Ku Autoantigen | 1 | 2000 | 10 | 0.040 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2000 | 16 | 0.040 |
Why?
| | Exons | 2 | 1999 | 353 | 0.040 |
Why?
| | Ubiquitins | 1 | 2000 | 38 | 0.040 |
Why?
| | CD146 Antigen | 1 | 2020 | 42 | 0.040 |
Why?
| | Glutathione Transferase | 1 | 2000 | 101 | 0.040 |
Why?
| | Peptides, Cyclic | 1 | 2001 | 266 | 0.040 |
Why?
| | Phosphates | 2 | 1993 | 181 | 0.040 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1999 | 55 | 0.040 |
Why?
| | Nucleic Acid Hybridization | 2 | 1990 | 189 | 0.040 |
Why?
| | Phosphotyrosine | 1 | 1998 | 40 | 0.040 |
Why?
| | Receptors, Growth Factor | 1 | 1998 | 56 | 0.040 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 1998 | 47 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 1998 | 71 | 0.040 |
Why?
| | Imidazoles | 1 | 2000 | 255 | 0.040 |
Why?
| | Protein Folding | 1 | 2000 | 278 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 159 | 0.040 |
Why?
| | Sp1 Transcription Factor | 1 | 1998 | 25 | 0.040 |
Why?
| | Immunoassay | 2 | 1989 | 113 | 0.040 |
Why?
| | Suppression, Genetic | 1 | 1998 | 24 | 0.040 |
Why?
| | Cyclin B | 1 | 1997 | 16 | 0.030 |
Why?
| | Cyclin A | 1 | 1997 | 18 | 0.030 |
Why?
| | Glycoproteins | 1 | 2000 | 358 | 0.030 |
Why?
| | Hydrocortisone | 3 | 1985 | 318 | 0.030 |
Why?
| | Dihydrotestosterone | 3 | 1979 | 44 | 0.030 |
Why?
| | Rats | 9 | 1991 | 5637 | 0.030 |
Why?
| | Cell Compartmentation | 3 | 1989 | 53 | 0.030 |
Why?
| | Isomerism | 1 | 1997 | 56 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1997 | 74 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 281 | 0.030 |
Why?
| | G1 Phase | 1 | 1997 | 72 | 0.030 |
Why?
| | Middle Aged | 6 | 2013 | 34647 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1997 | 74 | 0.030 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 2 | 2008 | 24 | 0.030 |
Why?
| | Biological Transport | 1 | 1998 | 410 | 0.030 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 1997 | 40 | 0.030 |
Why?
| | Yeasts | 1 | 1997 | 52 | 0.030 |
Why?
| | Autoantigens | 1 | 2000 | 426 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 1998 | 212 | 0.030 |
Why?
| | Blood Platelets | 2 | 1994 | 437 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 1986 | 136 | 0.030 |
Why?
| | Cyclin-Dependent Kinases | 1 | 1997 | 131 | 0.030 |
Why?
| | Photochemistry | 2 | 1990 | 133 | 0.030 |
Why?
| | Gene Expression | 3 | 2006 | 1492 | 0.030 |
Why?
| | Chromatin | 1 | 2000 | 533 | 0.030 |
Why?
| | Centrifugation, Density Gradient | 4 | 1983 | 40 | 0.030 |
Why?
| | Pyridines | 1 | 2000 | 557 | 0.030 |
Why?
| | Precipitin Tests | 2 | 2000 | 98 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2001 | 1158 | 0.030 |
Why?
| | Adult | 5 | 2013 | 39391 | 0.030 |
Why?
| | Prognosis | 4 | 2009 | 4080 | 0.030 |
Why?
| | Molecular Structure | 1 | 1996 | 503 | 0.030 |
Why?
| | Protein Kinases | 2 | 2008 | 308 | 0.030 |
Why?
| | TATA Box | 1 | 1994 | 22 | 0.030 |
Why?
| | Biopolymers | 1 | 1994 | 33 | 0.030 |
Why?
| | Adenosine Diphosphate | 1 | 1994 | 82 | 0.030 |
Why?
| | Estradiol Congeners | 3 | 1981 | 3 | 0.030 |
Why?
| | Chromatography, DEAE-Cellulose | 2 | 1985 | 13 | 0.030 |
Why?
| | Risk Factors | 1 | 2008 | 10482 | 0.030 |
Why?
| | Glucocorticoids | 6 | 2000 | 534 | 0.030 |
Why?
| | Genes, jun | 1 | 1993 | 10 | 0.030 |
Why?
| | Genes, fos | 1 | 1993 | 37 | 0.030 |
Why?
| | Antibodies | 2 | 1986 | 411 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1995 | 1094 | 0.030 |
Why?
| | Aneuploidy | 1 | 1994 | 89 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 1993 | 78 | 0.020 |
Why?
| | Macromolecular Substances | 2 | 1983 | 226 | 0.020 |
Why?
| | Karyotyping | 1 | 2012 | 104 | 0.020 |
Why?
| | Castration | 4 | 1982 | 14 | 0.020 |
Why?
| | Serotonin | 1 | 1994 | 323 | 0.020 |
Why?
| | Reference Values | 1 | 1994 | 807 | 0.020 |
Why?
| | Ploidies | 1 | 1992 | 19 | 0.020 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 2 | 1985 | 24 | 0.020 |
Why?
| | Ultraviolet Rays | 2 | 1985 | 401 | 0.020 |
Why?
| | Clone Cells | 1 | 1992 | 267 | 0.020 |
Why?
| | Serine | 2 | 2003 | 148 | 0.020 |
Why?
| | Cytokines | 1 | 1999 | 2100 | 0.020 |
Why?
| | DNA Probes | 1 | 1990 | 59 | 0.020 |
Why?
| | Codon | 1 | 1990 | 92 | 0.020 |
Why?
| | Cell Cycle Checkpoints | 1 | 2011 | 97 | 0.020 |
Why?
| | Rabbits | 1 | 1991 | 754 | 0.020 |
Why?
| | Peptide Chain Initiation, Translational | 1 | 1990 | 44 | 0.020 |
Why?
| | Radioligand Assay | 1 | 1989 | 37 | 0.020 |
Why?
| | Acceleration | 1 | 1969 | 36 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 197 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2009 | 44 | 0.020 |
Why?
| | Estrogen Receptor beta | 2 | 2000 | 41 | 0.020 |
Why?
| | Cyanogen Bromide | 1 | 1989 | 1 | 0.020 |
Why?
| | Neoplasms | 1 | 2004 | 2747 | 0.020 |
Why?
| | Peptide Mapping | 1 | 1989 | 65 | 0.020 |
Why?
| | Formaldehyde | 1 | 1989 | 67 | 0.020 |
Why?
| | Trypsin | 1 | 1989 | 76 | 0.020 |
Why?
| | Antigen-Antibody Complex | 2 | 1987 | 87 | 0.020 |
Why?
| | Mice, SCID | 1 | 2009 | 367 | 0.020 |
Why?
| | Mesoderm | 1 | 2009 | 144 | 0.020 |
Why?
| | Endometrial Hyperplasia | 1 | 2008 | 8 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 1989 | 386 | 0.020 |
Why?
| | Testosterone Congeners | 2 | 1979 | 9 | 0.020 |
Why?
| | Tissue Array Analysis | 1 | 2008 | 52 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.020 |
Why?
| | Microtubules | 1 | 2011 | 286 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 37 | 0.020 |
Why?
| | Phosphorus Radioisotopes | 1 | 1987 | 27 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 600 | 0.020 |
Why?
| | DNA Primers | 2 | 1998 | 510 | 0.020 |
Why?
| | Hysterectomy | 1 | 2008 | 138 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 197 | 0.020 |
Why?
| | 3-Hydroxysteroid Dehydrogenases | 1 | 1986 | 9 | 0.020 |
Why?
| | Steroid Hydroxylases | 1 | 1986 | 19 | 0.020 |
Why?
| | Protein C Inhibitor | 1 | 2006 | 1 | 0.020 |
Why?
| | Chromatography, Thin Layer | 1 | 1986 | 27 | 0.020 |
Why?
| | Chromatography, Gas | 1 | 1986 | 33 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1989 | 595 | 0.020 |
Why?
| | Ligases | 1 | 2006 | 32 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2006 | 60 | 0.020 |
Why?
| | Half-Life | 1 | 1986 | 146 | 0.020 |
Why?
| | Cadherins | 1 | 2008 | 202 | 0.020 |
Why?
| | RNA | 2 | 2005 | 930 | 0.020 |
Why?
| | Heterotrimeric GTP-Binding Proteins | 1 | 2006 | 12 | 0.020 |
Why?
| | Stress, Physiological | 1 | 1969 | 454 | 0.020 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2006 | 27 | 0.020 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2006 | 46 | 0.010 |
Why?
| | Androstenes | 1 | 2005 | 17 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2005 | 36 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1986 | 336 | 0.010 |
Why?
| | Desogestrel | 1 | 2005 | 46 | 0.010 |
Why?
| | Polymers | 1 | 1989 | 495 | 0.010 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 1985 | 3 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1998 | 1056 | 0.010 |
Why?
| | Cell Fractionation | 2 | 1982 | 54 | 0.010 |
Why?
| | Cricetinae | 2 | 1999 | 301 | 0.010 |
Why?
| | Amino Acids | 1 | 1988 | 497 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2005 | 149 | 0.010 |
Why?
| | RNA Interference | 1 | 2006 | 469 | 0.010 |
Why?
| | Calcitriol | 1 | 1985 | 59 | 0.010 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1985 | 69 | 0.010 |
Why?
| | Sucrose | 1 | 2004 | 111 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2004 | 97 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2006 | 325 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 1989 | 641 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 2006 | 198 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2008 | 1401 | 0.010 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1986 | 614 | 0.010 |
Why?
| | NIH 3T3 Cells | 1 | 2004 | 149 | 0.010 |
Why?
| | Homeostasis | 1 | 1988 | 636 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 748 | 0.010 |
Why?
| | Aged | 3 | 2012 | 24746 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 1983 | 131 | 0.010 |
Why?
| | Butadienes | 1 | 2003 | 37 | 0.010 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2003 | 50 | 0.010 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2003 | 122 | 0.010 |
Why?
| | Lymphocytes | 1 | 1985 | 398 | 0.010 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2003 | 98 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2004 | 718 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1982 | 80 | 0.010 |
Why?
| | Hypophysectomy | 3 | 1977 | 15 | 0.010 |
Why?
| | Nitriles | 1 | 2003 | 188 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2004 | 627 | 0.010 |
Why?
| | Butyrates | 1 | 1982 | 61 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1134 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 1985 | 528 | 0.010 |
Why?
| | Deoxyadenosines | 1 | 1980 | 9 | 0.010 |
Why?
| | Dogs | 1 | 1982 | 427 | 0.010 |
Why?
| | Y-Box-Binding Protein 1 | 1 | 2000 | 6 | 0.010 |
Why?
| | NFI Transcription Factors | 1 | 2000 | 8 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2004 | 1268 | 0.010 |
Why?
| | Diethylstilbestrol | 2 | 1979 | 9 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 1984 | 1057 | 0.010 |
Why?
| | Culture Techniques | 1 | 1999 | 74 | 0.010 |
Why?
| | Aorta | 1 | 1982 | 424 | 0.010 |
Why?
| | Coumestrol | 1 | 1978 | 1 | 0.010 |
Why?
| | Mycotoxins | 1 | 1978 | 4 | 0.010 |
Why?
| | Coumarins | 1 | 1978 | 18 | 0.010 |
Why?
| | Isoflavones | 1 | 1978 | 26 | 0.010 |
Why?
| | Premenopause | 1 | 1999 | 122 | 0.010 |
Why?
| | Flavonoids | 1 | 1978 | 85 | 0.010 |
Why?
| | Subcellular Fractions | 1 | 1978 | 78 | 0.010 |
Why?
| | Insulin | 1 | 1988 | 2491 | 0.010 |
Why?
| | Gene Deletion | 1 | 1999 | 389 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 1998 | 311 | 0.010 |
Why?
| | Regression Analysis | 1 | 2000 | 1023 | 0.010 |
Why?
| | Remission, Spontaneous | 1 | 1977 | 40 | 0.010 |
Why?
| | Recurrence | 2 | 1978 | 1111 | 0.010 |
Why?
| | Postmenopause | 1 | 1999 | 371 | 0.010 |
Why?
| | Hypersensitivity | 1 | 2000 | 260 | 0.010 |
Why?
| | Adrenal Glands | 1 | 1977 | 80 | 0.010 |
Why?
| | Sex Factors | 1 | 1982 | 2063 | 0.010 |
Why?
| | Fluoxymesterone | 1 | 1975 | 2 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2008 | 7923 | 0.010 |
Why?
| | Ovary | 1 | 1977 | 225 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1984 | 1793 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2006 | 5909 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 1997 | 725 | 0.010 |
Why?
| | Cattle | 1 | 1994 | 998 | 0.010 |
Why?
| | Clostridium tetani | 1 | 1969 | 1 | 0.000 |
Why?
| | Nystagmus, Pathologic | 1 | 1969 | 17 | 0.000 |
Why?
| | Treatment Outcome | 1 | 2004 | 11181 | 0.000 |
Why?
| | Genetic Vectors | 1 | 1990 | 336 | 0.000 |
Why?
| | Peptides | 1 | 1994 | 979 | 0.000 |
Why?
| | Corticosterone | 1 | 1969 | 242 | 0.000 |
Why?
| | Salmonella typhimurium | 1 | 1969 | 185 | 0.000 |
Why?
| | Hybridomas | 1 | 1987 | 236 | 0.000 |
Why?
| | Adrenalectomy | 2 | 1977 | 70 | 0.000 |
Why?
| | Male | 3 | 1999 | 70179 | 0.000 |
Why?
| | Pindolol | 1 | 1985 | 4 | 0.000 |
Why?
| | Mice, Inbred BALB C | 1 | 1987 | 1275 | 0.000 |
Why?
| | Blood Proteins | 1 | 1985 | 250 | 0.000 |
Why?
| | Solubility | 1 | 1980 | 245 | 0.000 |
Why?
| | Zeranol | 1 | 1978 | 1 | 0.000 |
Why?
| | Zearalenone | 1 | 1978 | 2 | 0.000 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1978 | 53 | 0.000 |
Why?
| | Aminoglutethimide | 1 | 1977 | 5 | 0.000 |
Why?
| | Species Specificity | 1 | 1976 | 583 | 0.000 |
Why?
|
|
Horwitz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|